Cathay Biotech Stock Current Liabilities

688065 Stock   42.84  0.22  0.51%   
Cathay Biotech fundamentals help investors to digest information that contributes to Cathay Biotech's financial success or failures. It also enables traders to predict the movement of Cathay Stock. The fundamental analysis module provides a way to measure Cathay Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cathay Biotech stock.
The current year's Total Current Liabilities is expected to grow to about 3.6 B, whereas Non Current Liabilities Total is forecasted to decline to about 621.3 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cathay Biotech Company Current Liabilities Analysis

Cathay Biotech's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

 = 

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition

Cathay Total Current Liabilities

Total Current Liabilities

3.58 Billion

At present, Cathay Biotech's Total Current Liabilities is projected to increase significantly based on the last few years of reporting.
In accordance with the recently published financial statements, Cathay Biotech has a Current Liabilities of 0.0. This is 100.0% lower than that of the Chemicals sector and 100.0% lower than that of the Materials industry. The current liabilities for all China stocks is 100.0% higher than that of the company.

Did you try this?

Run Bonds Directory Now

   

Bonds Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

Cathay Fundamentals

About Cathay Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cathay Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cathay Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cathay Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Cathay Stock

Cathay Biotech financial ratios help investors to determine whether Cathay Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cathay with respect to the benefits of owning Cathay Biotech security.